Analysis of HIV-1 in mucosal tissue in elite suppressors

精英抑制者粘膜组织中 HIV-1 的分析

基本信息

  • 批准号:
    8209611
  • 负责人:
  • 金额:
    $ 23.43万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2011
  • 资助国家:
    美国
  • 起止时间:
    2011-09-20 至 2013-08-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Elite suppressors are HIV-1 infected patients who maintain viral loads of <50 copies/ml without antiretroviral therapy. Despite this excellent control of viral replication, these patients continue to have residual viremia as determined by the presence of latently infected CD4+ T cells that contain replication-competent HIV-1. Interestingly, the frequency of these latently infected cells in peripheral blood is much lower in ES than in patients on suppressive HAART regimens with undetectable viral loads. This might suggest that ES may be the best candidates for strategies that could lead to eradication of these cells. This would only hold true if the total burden of these cells was much lower in ES. We therefore propose to look at two different mucosal sites in ES. Studies have suggested that the frequency of latently infected CD4 T cells in the gut associated lymphoid tissue (GALT) is ten times higher than the frequency in peripheral CD4+ T cells in patients on HAART. We want to determine whether this relationship holds true in ES. We will also look at the frequency of latently infected CD4+ T cells in the lungs of these patients so as to have a better approximation of the total burden of infected cells in ES. We have also recently provided evidence of ongoing HIV-1 replication and evolution of the very low level of HIV-1 present in the plasma of ES. There was very little evolution of the virus obtained from peripheral CD4+ T cells implying that CD4+ T cells in some other compartment are the source of the ongoing replication and evolution that lead to the plasma variants. By analyzing the sequence obtained from each compartment we would be able to determine the source of ongoing replication in the patients. This work will be important because it may suggest that ES are the best candidates for studies that could potentially cure HIV-1 infection by the eradication of latently infected CD4+ T cells. PUBLIC HEALTH RELEVANCE: Most patients infected with HIV-1 will develop a drop in their CD4 counts and frank AIDS as the virus replicates and destroys the immune system, however a unique group of untreated HIV-1-infected patients, termed Elite Suppressors (ES) are able to completely control the virus and do not develop AIDS (1-3). This project plans to measure the number of infected cells present in these patients and to determine the relationship between viruses from different tissues. The results may be applicable to the development of strategies for the eradication of HIV-1.
描述(由申请人提供):精英抑制者是HIV-1感染患者,在没有抗逆转录病毒治疗的情况下维持病毒载量<50拷贝/ml。尽管病毒复制得到了很好的控制,但这些患者仍然存在残留的病毒血症,这是由潜伏感染的CD4+ T细胞的存在所决定的,这些细胞含有复制能力强的HIV-1。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

JOEL N BLANKSON其他文献

JOEL N BLANKSON的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('JOEL N BLANKSON', 18)}}的其他基金

Eradication of clonally expanded CD4+ T cells
消除克隆扩增的 CD4 T 细胞
  • 批准号:
    10621808
  • 财政年份:
    2022
  • 资助金额:
    $ 23.43万
  • 项目类别:
Eradication of clonally expanded CD4+ T cells
消除克隆扩增的 CD4 T 细胞
  • 批准号:
    10548015
  • 财政年份:
    2022
  • 资助金额:
    $ 23.43万
  • 项目类别:
mRNA vaccine responses in PLWH
PLWH 中的 mRNA 疫苗反应
  • 批准号:
    10687989
  • 财政年份:
    2022
  • 资助金额:
    $ 23.43万
  • 项目类别:
mRNA vaccine responses in PLWH
PLWH 中的 mRNA 疫苗反应
  • 批准号:
    10402541
  • 财政年份:
    2022
  • 资助金额:
    $ 23.43万
  • 项目类别:
Optimization of high throughput viral outgrowth assays for the detection of HIV-1 reservoirs
用于检测 HIV-1 病毒库的高通量病毒生长检测的优化
  • 批准号:
    10177855
  • 财政年份:
    2018
  • 资助金额:
    $ 23.43万
  • 项目类别:
A mouse viral outgrowth assay for the detection of residual HIV-1 reservoirs
用于检测残留 HIV-1 病毒库的小鼠病毒生长测定
  • 批准号:
    9298573
  • 财政年份:
    2015
  • 资助金额:
    $ 23.43万
  • 项目类别:
A mouse viral outgrowth assay for the detection of residual HIV-1 reservoirs
用于检测残留 HIV-1 病毒库的小鼠病毒生长测定
  • 批准号:
    8965588
  • 财政年份:
    2015
  • 资助金额:
    $ 23.43万
  • 项目类别:
Phenotypic analysis of latently infected CD4+ T cells.
潜伏感染的 CD4 T 细胞的表型分析。
  • 批准号:
    8713921
  • 财政年份:
    2013
  • 资助金额:
    $ 23.43万
  • 项目类别:
Phenotypic analysis of latently infected CD4+ T cells.
潜伏感染的 CD4 T 细胞的表型分析。
  • 批准号:
    8610757
  • 财政年份:
    2013
  • 资助金额:
    $ 23.43万
  • 项目类别:
Analysis of HIV-1 in mucosal tissue in elite suppressors
精英抑制者粘膜组织中 HIV-1 的分析
  • 批准号:
    8333997
  • 财政年份:
    2011
  • 资助金额:
    $ 23.43万
  • 项目类别:

相似海外基金

RESISTANCE OF HIV-1 TO ANTI-RETROVIRAL AGENTS
HIV-1 对抗逆转录病毒药物的耐药性
  • 批准号:
    3030975
  • 财政年份:
    1993
  • 资助金额:
    $ 23.43万
  • 项目类别:
POLYMERICS DELIVERY SYSTEMS FOR ANTI-RETROVIRAL AGENTS
抗逆转录病毒药物的聚合物递送系统
  • 批准号:
    3489187
  • 财政年份:
    1990
  • 资助金额:
    $ 23.43万
  • 项目类别:
DEVELOPMENTAL VIROLOGY RESEARCH--RESISTANCE TO ANTI-RETROVIRAL AGENTS
发育病毒学研究——抗逆转录病毒药物的耐药性
  • 批准号:
    2335293
  • 财政年份:
  • 资助金额:
    $ 23.43万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了